Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function
暂无分享,去创建一个
L. Raymond | C. Cepeda | M. Levine | A. Milnerwood | C. M. Gladding | V. André | M. S. Levine | L. A. Raymond | V. M. André | C. Cepeda | A. J. Milnerwood | Clare M. Gladding
[1] G. Rebec,et al. Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: Variations with behavioral state and repeated ascorbate treatment , 2006, Neuroscience.
[2] S. Lipton. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.
[3] P. Greengard,et al. Regulation of NMDA receptor trafficking by amyloid-β , 2005, Nature Neuroscience.
[4] L. Raymond,et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease , 2004, Molecular and Cellular Neuroscience.
[5] C. Cepeda,et al. Differential sensitivity of medium‐ and large‐sized striatal neurons to NMDA but not kainate receptor activation in the rat , 2001, The European journal of neuroscience.
[6] Y. Smith,et al. The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat , 1990, Brain Research.
[7] Nicola Biagio Mercuri,et al. Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine , 2009, Movement disorders : official journal of the Movement Disorder Society.
[8] D. Sibley,et al. Striatal neurochemical changes in transgenic models of Huntington's disease , 2002, Journal of neuroscience research.
[9] J. Bolam,et al. Synaptic organisation of the basal ganglia , 2000, Journal of anatomy.
[10] I. Divac,et al. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain , 1981, Neuroscience.
[11] Bruce Fischl,et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.
[12] He Li,et al. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. , 2003, Human molecular genetics.
[13] C. Cepeda,et al. Dopamine and Glutamate in Huntington's Disease: A Balancing Act , 2010, CNS neuroscience & therapeutics.
[14] Jacki Y. Brown,et al. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. , 2006, Human molecular genetics.
[15] J. Coyle,et al. In situ injection of kainic acid: A new method for selectively lesioning neuronal cell bodies while sparing axons of passage , 1978, The Journal of comparative neurology.
[16] L. Raymond,et al. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease , 2010, Trends in Neurosciences.
[17] S. Folstein,et al. Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.
[18] Hilmar Bading,et al. Nuclear Calcium Signaling Controls Expression of a Large Gene Pool: Identification of a Gene Program for Acquired Neuroprotection Induced by Synaptic Activity , 2009, PLoS genetics.
[19] C. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. , 1992, Annual review of neuroscience.
[20] Carlos Cepeda,et al. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.
[21] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[22] K. Davies,et al. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices , 2009, Neuroscience.
[23] Anatol C. Kreitzer,et al. Distinct Roles of GABAergic Interneurons in the Regulation of Striatal Output Pathways , 2010, The Journal of Neuroscience.
[24] D. Bredt,et al. Ion Channel Clustering by Membrane-associated Guanylate Kinases , 2000, The Journal of Biological Chemistry.
[25] Michael R. Hayden,et al. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease , 2008, Neurobiology of Disease.
[26] E Maran,et al. Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.
[27] E. Stern,et al. Functional Changes in Neocortical Activity in Huntington's Disease Model Mice: An in vivo Intracellular Study , 2011, Front. Syst. Neurosci..
[28] G. Uhl,et al. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: high levels of preproenkephalin expression depend on cerebral cortical afferents , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[29] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[30] J. Lucas,et al. Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: Role in excitotoxicity , 2009, Neurobiology of Disease.
[31] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[32] S. Hersch,et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. , 2002, Human molecular genetics.
[33] Yvette E. Fisher,et al. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids , 2010, The European journal of neuroscience.
[34] M. Chesselet,et al. Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice , 2002, The Journal of Neuroscience.
[35] S. W. Davies,et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Penney,et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. , 1990, The New England journal of medicine.
[37] M. Ehlers. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system , 2003, Nature neuroscience.
[38] J. Olson,et al. Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.
[39] Françoise Condé,et al. Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.
[40] M. Chesselet,et al. Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.
[41] G. Egan,et al. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease , 2008, Brain Research Reviews.
[42] J. Coyle,et al. Striatal lesions with kainic acid: neurochemical characteristics , 1977, Brain Research.
[43] P. Greengard,et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[44] Carlos Cepeda,et al. Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.
[45] R. Dingledine,et al. The glutamate receptor ion channels. , 1999, Pharmacological reviews.
[46] J. Coyle,et al. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.
[47] P. Ghazal,et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses , 2008, Nature Neuroscience.
[48] C. Cepeda,et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease , 2007, Molecular Neurodegeneration.
[49] J. Penney,et al. Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.
[50] Thomas Walther,et al. Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.
[51] R. Duncan,et al. Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand , 2008, The Journal of Neuroscience.
[52] Max Kleiman-Weiner,et al. Differential electrophysiological properties of dopamine D1 and D2 receptor‐containing striatal medium‐sized spiny neurons , 2008, The European journal of neuroscience.
[53] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[54] A. Morton,et al. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation , 2006, Brain Research Bulletin.
[55] Wolfgang Eisenmenger,et al. Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington’s disease , 2009, Acta Neuropathologica.
[56] D. Surmeier,et al. Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study. , 1996, Molecular pharmacology.
[57] K. Murphy,et al. Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease , 2007, Brain Research Bulletin.
[58] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[59] B. Gloss,et al. Drd1a-tdTomato BAC Transgenic Mice for Simultaneous Visualization of Medium Spiny Neurons in the Direct and Indirect Pathways of the Basal Ganglia , 2008, The Journal of Neuroscience.
[60] Yvette E. Fisher,et al. SYSTEMS NEUROSCIENCE ORIGINAL RESEARCH ARTICLE , 2011 .
[61] Alexander Z. Harris,et al. Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices , 2007, The Journal of physiology.
[62] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[63] G. Landwehrmeyer,et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[64] A M Graybiel,et al. Cortically Driven Immediate-Early Gene Expression Reflects Modular Influence of Sensorimotor Cortex on Identified Striatal Neurons in the Squirrel Monkey , 1997, The Journal of Neuroscience.
[65] M. Chesselet,et al. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice , 2008, Neuroscience.
[66] M. Hayden,et al. Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity , 2004, Journal of Biological Chemistry.
[67] L. Raymond,et al. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.
[68] R. Petralia,et al. Organization of NMDA receptors at extrasynaptic locations , 2010, Neuroscience.
[69] D. Purpura,et al. Recruiting Extrasynaptic NMDA Receptors Augments Synaptic Signaling , 2007 .
[70] S. Lipton,et al. Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses , 2010, The Journal of Neuroscience.
[71] Marian DiFiglia,et al. Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.
[72] David S Tuch,et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.
[73] D. James Surmeier,et al. Re-emergence of striatal cholinergic interneurons in movement disorders , 2007, Trends in Neurosciences.
[74] Francois Gonon,et al. Intratelencephalic corticostriatal neurons equally excite striatonigral and striatopallidal neurons and their discharge activity is selectively reduced in experimental parkinsonism , 2008, The European journal of neuroscience.
[75] S. Lipton,et al. Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.
[76] Carlos Cepeda,et al. Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.
[77] Carlos Cepeda,et al. Dissecting the Contribution of Individual Receptor Subunits to the Enhancement of N-methyl-d-Aspartate Currents by Dopamine D1 Receptor Activation in Striatum , 2011, Front. Syst. Neurosci..
[78] Charles J. Wilson,et al. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons , 2008, Brain Research Reviews.
[79] Robert C. Malenka,et al. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models , 2007, Nature.
[80] Y. Smith,et al. The thalamostriatal system: a highly specific network of the basal ganglia circuitry , 2004, Trends in Neurosciences.
[81] J. Kemp,et al. Developmental Changes in NMDA Receptor Glycine Affinity and Ifenprodil Sensitivity Reveal Three Distinct Populations of NMDA Receptors in Individual Rat Cortical Neurons , 1998, The Journal of Neuroscience.
[82] P. Brundin,et al. Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.
[83] D. Riche,et al. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon , 1990, Experimental Neurology.
[84] M. Sheng,et al. Differential Roles of NR2A- and NR2B-Containing NMDA Receptors in Ras-ERK Signaling and AMPA Receptor Trafficking , 2005, Neuron.
[85] Carlos Cepeda,et al. Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease , 2009, The Journal of Neuroscience.
[86] C. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.
[87] A. Kriegstein,et al. Glutamate neurotoxicity in cortical cell culture , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[88] A. Morton,et al. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation , 2000, Journal of neurocytology.
[89] L. Raymond,et al. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice , 2010, Neuron.
[90] L. Raymond,et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease , 2012, Neurobiology of Disease.
[91] Jan Kassubek,et al. Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study , 2004, Neuroreport.
[92] C. Hillard,et al. Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[93] S. Cull-Candy,et al. Role of Distinct NMDA Receptor Subtypes at Central Synapses , 2004, Science's STKE.
[94] Rand Askalan,et al. Tyrosine Phosphatase STEP Is a Tonic Brake on Induction of Long-Term Potentiation , 2002, Neuron.
[95] L. Ellerby,et al. Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.
[96] Angus C. Nairn,et al. Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.
[97] J. Hodges,et al. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers , 2001, Psychiatry Research.
[98] M. Hayden,et al. Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.
[99] Patrik Brundin,et al. Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.
[100] D. Surmeier,et al. Dichotomous Anatomical Properties of Adult Striatal Medium Spiny Neurons , 2008, The Journal of Neuroscience.
[101] Sheree D. Cherry. Calcium channel dysfunction in Huntington's disease , 2009 .
[102] M. Hayden,et al. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.
[103] P. Mcgeer,et al. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.
[104] Claire-Anne Gutekunst,et al. Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins , 2004, Neuron.
[105] Carlos Cepeda,et al. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease , 2010, ASN neuro.
[106] C. Gerfen,et al. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[107] A. Buisson,et al. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[108] Charles J. Wilson,et al. GABAergic microcircuits in the neostriatum , 2004, Trends in Neurosciences.
[109] Elsdon Storey,et al. Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.
[110] M. Hayden,et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. , 2008, Brain : a journal of neurology.
[111] D. Coulter,et al. Fyn-mediated Phosphorylation of NR2B Tyr-1336 Controls Calpain-mediated NR2B Cleavage in Neurons and Heterologous Systems* , 2007, Journal of Biological Chemistry.
[112] J. Penney,et al. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia , 1990, Annals of neurology.
[113] J. Isaac,et al. Casein Kinase 2 Regulates the NR2 Subunit Composition of Synaptic NMDA Receptors , 2010, Neuron.
[114] Yu Deng,et al. Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease , 2009, The Journal of Neuroscience.
[115] P. Mcgeer,et al. A glutamatergic corticostriatal path? , 1977, Brain Research.
[116] H. Steinbusch,et al. Hyperdopaminergic Status in Experimental Huntington Disease , 2010, Journal of neuropathology and experimental neurology.
[117] L. Raymond,et al. Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.
[118] E. Cattaneo,et al. Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.
[119] S. T. Kitai,et al. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[120] G. Westbrook,et al. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. , 2006, Journal of neurophysiology.
[121] I. Módy,et al. Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.
[122] A. Laverghetta,et al. Differential morphology of pyramidal tract‐type and intratelencephalically projecting‐type corticostriatal neurons and their intrastriatal terminals in rats , 2003, The Journal of comparative neurology.
[123] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[124] D J Brooks,et al. Microglial activation correlates with severity in Huntington disease , 2006, Neurology.
[125] D. Rubinsztein,et al. Huntington's disease: from pathology and genetics to potential therapies. , 2008, The Biochemical journal.
[126] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[127] R. Nicoll,et al. Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[128] Carlos Cepeda,et al. Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.
[129] K. Roche,et al. Regulation of NMDA receptors by phosphorylation , 2007, Neuropharmacology.
[130] H. Tanila,et al. Orexin loss in Huntington's disease. , 2005, Human molecular genetics.
[131] A. Graybiel. Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.
[132] H. Bading,et al. Hypoxic/ischemic conditions induce expression of the putative pro-death gene Clca1 via activation of extrasynaptic N-methyl-d-aspartate receptors , 2009, Neuroscience.
[133] G. Deuschl,et al. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation , 2008, Movement disorders : official journal of the Movement Disorder Society.
[134] J. Penney,et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis , 1995, Neuroscience.
[135] H. Parthasarathy,et al. Local Release of GABAergic Inhibition in the Motor Cortex Induces Immediate-Early Gene Expression in Indirect Pathway Neurons of the Striatum , 1997, The Journal of Neuroscience.
[136] David H Salat,et al. Complexity and Heterogeneity: What Drives the Ever‐changing Brain in Huntington's Disease? , 2008, Annals of the New York Academy of Sciences.
[137] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[138] M. Mayer,et al. Permeation and block of N‐methyl‐D‐aspartic acid receptor channels by divalent cations in mouse cultured central neurones. , 1987, The Journal of physiology.
[139] Roger L Albin,et al. Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[140] E. Bird,et al. Chemical pathology of Huntington's disease. , 1980, Annual review of pharmacology and toxicology.
[141] Carlos Cepeda,et al. Genetic mouse models of Huntington’s disease: focus on electrophysiological mechanisms , 2010, ASN neuro.
[142] H. Bading,et al. A calcium microdomain near NMDA receptors: on switch for ERK-dependent synapse-to-nucleus communication , 2001, Nature Neuroscience.
[143] L. Raymond,et al. Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[144] R. Nicoll,et al. PSD-95 involvement in maturation of excitatory synapses. , 2000, Science.
[145] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[146] J. Penney,et al. NMDA receptor losses in putamen from patients with Huntington's disease. , 1988, Science.
[147] Carlos Cepeda,et al. The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.
[148] Jing Fan,et al. Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease , 2009, The Journal of Neuroscience.
[149] J. Bibb,et al. Extrasynaptic NMDA Receptors Couple Preferentially to Excitotoxicity via Calpain-Mediated Cleavage of STEP , 2009, The Journal of Neuroscience.
[150] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[151] M. Ehrlich,et al. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. , 2008, Human molecular genetics.
[152] A. Mahal,et al. Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.
[153] Stephen B. Dunnett,et al. Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation , 1999, The Journal of Neuroscience.
[154] M. MacDonald,et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. , 2000, Human molecular genetics.
[155] C. Gerfen,et al. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons , 1999, Neuroscience.
[156] R. Schwarcz,et al. II: Excitotoxic models for neurodegenerative disorders , 1984 .
[157] M. Hayden,et al. Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors , 2006, The Journal of Neuroscience.
[158] J. Tsien,et al. In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.
[159] J. Xuereb,et al. The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain , 1996, Neuroscience.
[160] D. Surmeier,et al. Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons , 1996, The Journal of Neuroscience.
[161] Jun O. Liu,et al. Calpain-dependent cleavage of cain/cabin1 activates calcineurin to mediate calcium-triggered cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[162] M. Bennett,et al. Postsynaptic Density Protein-95 Regulates NMDA Channel Gating and Surface Expression , 2004, The Journal of Neuroscience.
[163] Scott H Chandler,et al. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. , 2005, Journal of neurophysiology.
[164] Masahiko Watanabe,et al. Role of the Carboxy-Terminal Region of the GluRε2 Subunit in Synaptic Localization of the NMDA Receptor Channel , 1998, Neuron.
[165] W. Nauta,et al. Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry , 1983, Neuroscience.
[166] G. Johnson,et al. Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells , 2006, Journal of Biological Chemistry.
[167] Y. Kawaguchi,et al. Recurrent Connection Patterns of Corticostriatal Pyramidal Cells in Frontal Cortex , 2006, The Journal of Neuroscience.
[168] J. Epplen,et al. Chorea Huntington: A Rare Case with Childhood Onset , 2002, Neuropediatrics.
[169] L. Raymond,et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease , 2006, Neurobiology of Disease.
[170] A E Rosser,et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. , 1998, Brain : a journal of neurology.
[171] Shaun S. Sanders,et al. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease , 2010, Neurobiology of Disease.
[172] S. Hersch,et al. Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.
[173] Yvette E. Fisher,et al. Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease , 2011, The Journal of Neuroscience.
[174] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[175] Yen F. Tai,et al. Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.
[176] G. Reynolds,et al. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease , 2002, Journal of neurochemistry.
[177] Timothy H Murphy,et al. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. , 2004, Journal of neurophysiology.
[178] D. Bredt,et al. Lipid- and protein-mediated multimerization of PSD-95: implications for receptor clustering and assembly of synaptic protein networks , 2003, Journal of Cell Science.
[179] L. Bäckman,et al. Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. , 2001, Scandinavian journal of psychology.
[180] Michael R. Hayden,et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin , 2009, Nature Medicine.
[181] E. Spokes. The neurochemistry of Huntington's chorea , 1981, Trends in Neurosciences.
[182] D. Sengelaub,et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse , 2008, Neuroscience.
[183] M. Guillermier,et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects , 2010, Human molecular genetics.
[184] Neal Sweeney,et al. Synaptic Strength Regulated by Palmitate Cycling on PSD-95 , 2002, Cell.
[185] Kai Chang,et al. The Synaptic Localization of NR2B-Containing NMDA Receptors Is Controlled by Interactions with PDZ Proteins and AP-2 , 2005, Neuron.
[186] A. Parent,et al. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease , 2000, Brain Research Reviews.
[187] Coyle Jt. An animal model for Huntington's disease. , 1979 .
[188] T. Bliss,et al. A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.
[189] L. Cif,et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. , 2008, Journal of neurosurgery.
[190] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[191] Scott J Barton,et al. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. , 2008, Journal of neurophysiology.
[192] G. Bernardi,et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.
[193] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[194] Robert Lipsky,et al. The excitoprotective effect of N‐methyl‐d‐aspartate receptors is mediated by a brain‐derived neurotrophic factor autocrine loop in cultured hippocampal neurons , 2005, Journal of neurochemistry.
[195] R. Neumar,et al. Selective Activation Induced Cleavage of the NR2B Subunit by Calpain , 2003, The Journal of Neuroscience.
[196] R N Gunn,et al. Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.
[197] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[198] Y. Ben-Ari,et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal‐regulated kinases (ERK) activity in cultured rat hippocampal neurons , 2006, The Journal of physiology.
[199] Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2003 .
[200] M. Giordano,et al. The quinolinic acid model of Huntington's disease: Locomotor abnormalities , 1989, Experimental Neurology.
[201] Jacqueline K. White,et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion , 1997, Nature Genetics.
[202] Kemp Jm. The site of termination of afferent fibres on the neurones of the caudate nucleus. , 1970 .
[203] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[204] S. Goto,et al. An immunohistochemical investigation of the human neostriatum in huntington's disease , 1989, Annals of neurology.
[205] G. Sedvall,et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.
[206] Jane S. Paulsen. Functional imaging in Huntington's disease , 2009, Experimental Neurology.
[207] R. Albin,et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.
[208] L. Raymond,et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease , 2003, Neurobiology of Aging.
[209] R. Huganir,et al. Dual Palmitoylation of NR2 Subunits Regulates NMDA Receptor Trafficking , 2009, Neuron.
[210] R. Porter,et al. Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.
[211] I. Módy,et al. Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease , 2008, Neuroscience.
[212] T. Hökfelt,et al. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. , 1982, European journal of pharmacology.
[213] Jane S. Paulsen,et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[214] K. Roche,et al. Subunit-Specific Regulation of NMDA Receptor Endocytosis , 2004, The Journal of Neuroscience.
[215] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[216] D. Jane,et al. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. , 2000, The Journal of pharmacology and experimental therapeutics.
[217] A. Morton,et al. Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.
[218] R. Llinás,et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[219] Carlos Cepeda,et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.
[220] D. Geschwind,et al. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. , 2011, Human molecular genetics.
[221] S B Dunnett,et al. Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.
[222] L. Bäckman,et al. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.
[223] C. Cepeda,et al. Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.
[224] N. Déglon,et al. Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.
[225] S. Jones,et al. Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington’s disease , 2007, Neuroscience.
[226] Roberto Malinow,et al. Subunit-Specific NMDA Receptor Trafficking to Synapses , 2002, Neuron.
[227] M. Hayden,et al. Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.
[228] A. Reiner,et al. Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats , 2004, The Journal of Neuroscience.
[229] Jiahuai Han,et al. Distinct Requirements for p38α and c-Jun N-terminal Kinase Stress-activated Protein Kinases in Different Forms of Apoptotic Neuronal Death* , 2004, Journal of Biological Chemistry.
[230] J. Deniau,et al. Disinhibition as a basic process in the expression of striatal functions , 1990, Trends in Neurosciences.
[231] S. W. Davies,et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[232] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[233] J. Coyle,et al. Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.
[234] Jacki Y. Brown,et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. , 2006, Human molecular genetics.
[235] Ji-Yeon Shin,et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.
[236] D. Oorschot,et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. , 2010, Brain : a journal of neurology.
[237] B Fischl,et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.
[238] L. Raymond,et al. N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.
[239] H. D. Rosas,et al. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington’s disease , 2004, NeuroRX.
[240] P S Harper,et al. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. , 1996, Human molecular genetics.
[241] A. Tobin,et al. Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.
[242] D. Lucas,et al. The toxic effect of sodium L-glutamate on the inner layers of the retina. , 1957, A.M.A. archives of ophthalmology.
[243] M. Tymianski,et al. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. , 2003, Cell calcium.
[244] Cheng-Wei Lu,et al. Memantine depresses glutamate release through inhibition of voltage-dependent Ca2+ entry and protein kinase C in rat cerebral cortex nerve terminals: An NMDA receptor-independent mechanism , 2010, Neurochemistry International.
[245] M. Salter,et al. Regulation of NMDA Receptors by Kinases and Phosphatases , 2009 .
[246] M. Beal,et al. Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.
[247] Joseph B. Martin,et al. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.
[248] B. D. de Jong,et al. Changes in striatal dopamine D2 receptor binding in pre‐clinical Huntington’s disease , 2008, European journal of neurology.
[249] L. Raymond,et al. Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity , 2008, The Journal of Neuroscience.
[250] Philip A. Starr,et al. Pallidal neuronal discharge in Huntington's disease: Support for selective loss of striatal cells originating the indirect pathway , 2008, Experimental Neurology.
[251] R. Yasuda,et al. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. , 2003, Brain : a journal of neurology.
[252] M. M. Soundarapandian,et al. DAPK1 Interaction with NMDA Receptor NR2B Subunits Mediates Brain Damage in Stroke , 2010, Cell.
[253] R. Wightman,et al. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.
[254] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[255] H. Bading,et al. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.
[256] J. Penney,et al. Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.
[257] P. Soares-da-Silva,et al. Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission , 1992, Journal of neurochemistry.
[258] N. Hardingham,et al. Nuclear Ca2+ and the cAMP Response Element-Binding Protein Family Mediate a Late Phase of Activity-Dependent Neuroprotection , 2005, The Journal of Neuroscience.
[259] K. Chu,et al. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington’s disease , 2006, Brain Research.
[260] Carlos Cepeda,et al. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. , 2006, Journal of neurophysiology.
[261] C. Wilson,et al. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[262] K. Roche,et al. Molecular determinants of NMDA receptor internalization , 2001, Nature Neuroscience.
[263] D. Bredt,et al. Synaptic Targeting of the Postsynaptic Density Protein PSD-95 Mediated by Lipid and Protein Motifs , 1999, Neuron.
[264] H. Bading,et al. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.
[265] J. Tepper,et al. GABAA and GABAB antagonists differentially affect the firing pattern of substantia nigra dopaminergic neurons in vivo , 1999, Synapse.
[266] M. Hayden,et al. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.
[267] Peter S. Harper,et al. Huntington's disease , 1991 .
[268] D. Langbehn,et al. Earliest functional declines in Huntington disease , 2010, Psychiatry Research.
[269] Ruth Luthi-Carter,et al. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation , 2003, Neurobiology of Disease.
[270] H. Kita,et al. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations , 1988, Brain Research.
[271] A. Strafella,et al. Bilateral globus pallidus stimulation for Huntington's disease , 2004, Annals of neurology.
[272] R. Heumann,et al. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain , 2004, Neurobiology of Disease.
[273] H. Johnston,et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. , 1999, Human molecular genetics.
[274] M. Beal,et al. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[275] P. Calabresi,et al. Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons , 2006, Neurobiology of Disease.
[276] J. Penney,et al. Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. , 1999, Brain research. Molecular brain research.
[277] D. Coulter,et al. Specific proteolysis of the NR2 subunit at multiple sites by calpain , 2001, Journal of neurochemistry.
[278] C. Cepeda,et al. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function , 2011, ASN neuro.
[279] D. Choquet,et al. NMDA receptor surface mobility depends on NR2A-2B subunits , 2006, Proceedings of the National Academy of Sciences.
[280] M. Chesselet,et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.
[281] R. Albin,et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.
[282] A. Rasmussen,et al. Huntington disease in children: genotype-phenotype correlation. , 2000, Neuropediatrics.
[283] A. Weindl,et al. Sensory processing in Parkinson's and Huntington's disease: investigations with 3D H(2)(15)O-PET. , 1999, Brain : a journal of neurology.
[284] W. Strittmatter,et al. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. , 2003, Archives of biochemistry and biophysics.
[285] Ann Marie Craig,et al. NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo , 2007, The Journal of Neuroscience.
[286] Carlos Cepeda,et al. Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease , 2009, The Journal of Neuroscience.
[287] E. Richfield,et al. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients , 1995, Annals of neurology.
[288] S. Augood,et al. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.
[289] G. Westbrook,et al. The Incorporation of NMDA Receptors with a Distinct Subunit Composition at Nascent Hippocampal Synapses In Vitro , 1999, The Journal of Neuroscience.
[290] J. B. Martin,et al. Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.
[291] H. Manev,et al. NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones. , 1993, Neuroreport.
[292] M. Chesselet,et al. Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats , 2003, The Journal of comparative neurology.
[293] Scott J Barton,et al. Altered Information Processing in the Prefrontal Cortex of Huntington's Disease Mouse Models , 2008, The Journal of Neuroscience.